Option-related selling at Trillium Therapeutics (T:TRIL)

Jan Skvarka, CEO and Director, disposed of 600,000 Common Shares on a control or direction basis for registered holder Merrill Lynch, Pierce, Fenner & Smith Incorporated at prices ranging from US$11.530 to US$11.804 between December 14th and 17th, 2020. This represents a $8,933,209 divestment of the company's shares and an account share holdings change of -100.0%.

In addition, Robert Uger, a Senior Officer, sold 375,502 Common Shares on a control or direction basis for registered holder BMO Nesbitt Burns Inc at prices ranging from US$11.529 to US$12.192 between December 14th and 18th, 2020. This represents a $5,615,112 divestment of the company's shares and an account share holdings change of -100.0%.

Between the same dates, James Todd Parsons, CFO, disposed of 250,312 Common Shares on a control or direction basis for registered holder BMO Nesbitt Burns Inc at prices ranging from US$11.311 to US$12.717. This represents a $3,812,731 divestment of the company's shares and an account share holdings change of -100.0%.

Finally, Penka Petrova, a Senior Officer, disposed of 164,728 Common Shares on a control or direction basis for registered holder BMO Nesbitt Burns Inc at prices ranging from US$11.529 to US$11.850 between December 15th and 17th, 2020. This represents a $2,453,822 divestment of the company's shares and an account share holdings change of -100.0%.

Trillium Therapeutics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. The Company leads program, TTI-621, which is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (''do not eat'') signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (''eat'') signals. A Phase one clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with cancer is ongoing, and a second Phase one trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium Therapeutics Inc. (TRIL) has below median officer and director direct ownership compared to its mid-cap peers in the market, based on our estimate using SEDI data. According to recent regulatory filings, four insiders have divested a net amount of $20,814,875.